- Home
- ACIU vs REFI Comparison
ACIU vs REFI Comparison
Compare ACIU & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- REFI
- Stock Information
- Founded
- ACIU 2003
- REFI 2021
- Country
- ACIU Switzerland
- REFI United States
- Employees
- ACIU N/A
- REFI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- ACIU Health Care
- REFI Real Estate
- Exchange
- ACIU Nasdaq
- REFI Nasdaq
- Market Cap
- ACIU 332.4M
- REFI 306.1M
- IPO Year
- ACIU 2016
- REFI 2021
- Fundamental
- Price
- ACIU $2.71
- REFI $16.21
- Analyst Decision
- ACIU Strong Buy
- REFI Strong Buy
- Analyst Count
- ACIU 2
- REFI 3
- Target Price
- ACIU $12.00
- REFI $20.00
- AVG Volume (30 Days)
- ACIU 130.0K
- REFI 121.4K
- Earning Date
- ACIU 11-05-2024
- REFI 11-07-2024
- Dividend Yield
- ACIU N/A
- REFI 11.60%
- EPS Growth
- ACIU N/A
- REFI N/A
- EPS
- ACIU N/A
- REFI 2.00
- Revenue
- ACIU $48,505,404.00
- REFI $56,860,278.00
- Revenue This Year
- ACIU $85.33
- REFI N/A
- Revenue Next Year
- ACIU $80.69
- REFI $4.27
- P/E Ratio
- ACIU N/A
- REFI $8.11
- Revenue Growth
- ACIU 4097200.00
- REFI 6.49
- 52 Week Low
- ACIU $2.25
- REFI $14.82
- 52 Week High
- ACIU $5.14
- REFI $16.75
- Technical
- Relative Strength Index (RSI)
- ACIU 29.89
- REFI 58.66
- Support Level
- ACIU $2.62
- REFI $15.69
- Resistance Level
- ACIU $3.07
- REFI $16.24
- Average True Range (ATR)
- ACIU 0.15
- REFI 0.20
- MACD
- ACIU -0.04
- REFI -0.02
- Stochastic Oscillator
- ACIU 17.24
- REFI 90.32
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.